Opko Health Inc.
OPK Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
OPK Income Statement
OPK Balance Sheet
OPK Cash Flow
Recent trades of OPK by members of U.S. Congress
OPK Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
OPK Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
OPK Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by OPK's directors and management
Government lobbying spending instances
-
$25,000 Oct 31, 2024 Issue: Health Issues
-
$25,000 Jul 30, 2024 Issue: Health Issues
-
$25,000 Apr 04, 2024 Issue: None
-
$25,000 Feb 05, 2024 Issue: Health Issues
-
$25,000 Oct 02, 2023 Issue: Health Issues
-
$25,000 Aug 04, 2023 Issue: Health Issues
-
$25,000 Apr 21, 2023 Issue: Health Issues
-
$50,000 Jan 08, 2023 Issue: Health Issues
-
$50,000 Nov 02, 2022 Issue: Health Issues
-
$50,000 Jul 07, 2022 Issue: Health Issues
-
$50,000 May 05, 2022 Issue: Health Issues
-
$50,000 Feb 09, 2022 Issue: Health Issues
-
$50,000 Nov 03, 2021 Issue: Health Issues
-
$50,000 Aug 05, 2021 Issue: Health Issues
-
$50,000 May 03, 2021 Issue: Health Issues
-
$50,000 Feb 03, 2021 Issue: Health Issues
-
$60,000 Nov 04, 2020 Issue: Health Issues
-
$50,000 Aug 05, 2020 Issue: Health Issues
-
$50,000 Apr 26, 2020 Issue: Health Issues
-
$50,000 Jan 23, 2020 Issue: Health Issues
-
$51,000 Nov 18, 2019 Issue: Health Issues
-
$37,000 Jul 30, 2019 Issue: Health Issues
-
$37,000 Jul 30, 2019 Issue: Health Issues
-
$25,000 Aug 17, 2016 Issue: Health Issues
-
$25,000 Jul 06, 2016 Issue: None
-
$36,000 Mar 31, 2015 Issue: Health Issues
-
$40,000 Jan 20, 2015 Issue: Health Issues Veterans Medicare/Medicaid
-
$45,000 Nov 16, 2014 Issue: Health Issues Veterans Government Issues
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Hydrochloride salts of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and preparation process therefor Feb. 05, 2019
-
Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Jun. 19, 2018
-
Patent Title: Nk May. 15, 2018
-
Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Nov. 21, 2017
-
Patent Title: Nk Jun. 27, 2017
-
Patent Title: Nk Oct. 18, 2016
-
Patent Title: Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same May. 24, 2016
-
Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Feb. 16, 2016
-
Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Feb. 02, 2016
-
Patent Title: Intravenous formulations of neurokinin-1 antagonists Aug. 11, 2015
-
Patent Title: Hypersulfated disaccharide formulations Apr. 14, 2015
-
Patent Title: Nk1 antagonists Aug. 05, 2014
-
Patent Title: Nk1 antagonists Jun. 17, 2014
-
Patent Title: Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds Oct. 08, 2013
-
Patent Title: Hypersulfated disaccharide formulations Oct. 01, 2013
-
Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Jun. 25, 2013
-
Patent Title: Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Mar. 26, 2013
-
Patent Title: Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom Jan. 29, 2013
-
Patent Title: Nk Sep. 25, 2012
-
Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor May. 15, 2012
-
Patent Title: Nk Sep. 27, 2011
-
Patent Title: Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Jul. 19, 2011
-
Patent Title: Nk Mar. 08, 2011
-
Patent Title: Nk1 antagonists May. 04, 2010
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of OPK in WallStreetBets Daily Discussion
OPK News
Recent insights relating to OPK
CNBC Recommendations
Recent picks made for OPK stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in OPK
OPK Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view OPK Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More